Emris Pharma

Preventing EGFRi skin toxicities, enhancing patient quality of life & Compliance for Cancer Patients

Health Tech & Life Sciences
Private
Follow

Company Overview

Snapshot

Founded in May 2023 by Lyora Aharonov, Emris Pharma operates with 1–10 employees. The company secured its Pre-Seed funding round in May 2023, with NGT HealthCare II participating as a lead investor. This funding supported the launch of its innovative topical drug development.

Business overview

Emris Pharma is a Health Tech and Life Sciences company focused on developing novel small molecule, topically administered drugs to prevent skin toxicities induced by EGFR inhibitors (EGFRi). Its core product, SDT 011 (EMR-001), aims to improve the quality of life and treatment compliance for cancer patients by blocking the initial trigger of skin toxicity. The company targets a global market with unmet needs, anticipating growth due to new cancer treatment combinations involving EGFRi and emerging bi-specific antibodies.

Strategic signal

In June 2023, Emris Pharma, a spin-off of Hadasit and Yissum, officially launched the development of its innovative topical drug. This launch signals the company's entry into the pharmaceutical market with a focus on improving cancer patient care, indicating a strategic move towards addressing a significant unmet medical need and enhancing treatment adherence.

Log in to access full profile

Company Intelligence Q&A

When was Emris Pharma founded?
Emris Pharma was founded in May 2023.
Who are the founders of Emris Pharma?
Lyora Aharonov is a co-founder and CEO of Emris Pharma.
What is Emris Pharma's primary focus?
Emris Pharma focuses on developing a novel small molecule, topically administered drug to prevent skin toxicities induced by EGFR inhibitors, aiming to improve cancer patients' quality of life and compliance with therapy.
Which investors participated in Emris Pharma's Pre-Seed funding round?
In May 2023, Emris Pharma received Pre-Seed funding from NGT HealthCare II and the Israel Innovation Authority.
What is the significance of Emris Pharma's launch?
Emris Pharma launched in June 2023 as a spin-off of Hadasit and Yissum, initiating the development of a new topical drug designed to treat skin toxicities and improve the quality of life for cancer patients.
Log in to access full profile